Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
ChrysCapital has acquired a controlling 70.68% stake in Novartis India Limited. Dr. Vikas Gupta has been appointed MD & CEO, along with new Independent Directors, to drive strategy for a branded-generics platform.
Jul 29 2026 21:38:33
Novartis India Ltd - 500672 - Disclosure In Terms Of Regulation 29(2) Of The Securities And Exchange Board Of India (Substantial Acquisition Of Shares And Takeovers) ("SAST"), 2015.
Promoter Novartis AG sold 1.74 crore equity shares, representing 70.68% of Novartis India. The transaction was an off-market sale, resulting in Novartis AG ceasing to be a promoter and being reclassified as a public shareholder.
Jul 29 2026 19:22:00
Novartis India Ltd - 500672 - Disclosure In Terms Of Regulation 7(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015.
Novartis AG, the erstwhile promoter of Novartis India, sold 1,74,50,680 equity shares, representing 70.68% of the company's share capital, through an off-market transaction on July 29, 2026. The sale was valued at Rs. 137.69 crore, marking a major change in ownership.
Jul 29 2026 18:59:21
Novartis India Ltd - 500672 - Intimation Under Regulation 31A (10) And Other Applicable Provisions Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, ("SEBI Listing Regulations").
Novartis India's promoter, Novartis AG, has been reclassified from 'Promoter' to 'Public' category. This follows the divestment of a 70.68% equity stake to WaveRise Investments Limited and ChrysCapital Fund X, transferring company control on July 29, 2026.
Jul 29 2026 18:40:42
Novartis India Ltd - 500672 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners collectively acquired a 70.68% stake in Novartis India Limited. These entities are now classified as the promoters, having gained control through an off-market transfer.
Jul 29 2026 17:15:31
Novartis India Ltd - 500672 - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Novartis India Limited Held On Thursday, July 23, 2026.
Novartis India's board approved Q1 FY27 financial results on July 23, 2026. Revenue rose 18.57% YoY to ₹103.81 crores, and net profit increased 16.62% YoY to ₹32.21 crores, along with the Limited Review Report.
Jul 23 2026 12:54:23
Novartis India Ltd - 500672 - Post-Offer advertisement
Novartis India's open offer for 26% of its voting share capital has concluded, with 64.19 lakh shares accepted at Rs. 860.64 per share. This follows an underlying transaction where Acquirers gained 70.68% control.
Jul 10 2026 08:55:01
Novartis India Ltd - 500672 - Board Meeting Intimation for Intimation Of The Meeting Of Board Of Directors Of Novartis India Limited ("The Company").
Novartis India Limited's Board of Directors is scheduled to meet on July 23, 2026. The primary agenda is to consider and approve the unaudited financial results for the first quarter of FY27, ending June 30, 2026.
Jul 07 2026 15:04:29
Read More